DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement
Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
Yahoo Finance [Yahoo! Finance]
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease